Investors
Committed to providing timely, high-quality information
Welcome
Control Bionics Limited
Investor Relations
Our most recent key ASX announcements together with our corporate governance policies can be found here.
If you have any further questions regarding investing in Control Bionics Limited,
please contact Brett Crowley, Company Secretary, at brettcrowley@controlbionics.com or at +61 411 713 555.
Corporate Governance and Policies
Shareholder Communications
Receiving your shareholder communications electronically is the best way to stay informed and will assist CBL with minimising paper usage. If you haven’t already, we encourage you to make the switch to paperless communications and provide us with your email address. To make the change, login to your Automic investor portal, add your email address and select the communication options you would like to set to email. You can make a standing election as to how you would like to receive certain documents including annual reports, meeting-related documents (for example notices of meeting and proxy/voting forms) and payment statements. You can also make a one-off request to receive a document in physical or electronic form through the Automic portal. You will also be able to access Shareholder Documents such as our Annual Report, Notice of Meeting and other documents relating to shareholder meetings when they are published on our website or made available on the ASX platform.
News
- NeuroNode is now an Apple-Approved Assistive Tech DeviceControl Bionics is excited to announce that NeuroNode® has been listed as a third-party assistive technology device on Apple’s website. Apple’s inclusion of the NeuroNode in its Apple-approved assistive technologies underscores NueroNode’s versatility and effectiveness. Users can seamlessly integrate the NeuroNode with their Apple devices including iPads, iPhones, and computers,… Read more: NeuroNode is now an Apple-Approved Assistive Tech Device
- The ALS Association awards a prestigious Assistive Technology Grant to Control BionicsControl Bionics is thrilled to announce it has been awarded one of the prestigious ALS Association 2023 Assistive Technology Grants. The ALS Association is the leading ALS organization in the world and is working to make ALS a livable disease while urgently searching for new treatments and a cure. The grant… Read more: The ALS Association awards a prestigious Assistive Technology Grant to Control Bionics
- International Impact: A Message of HopeKiichi Otsuka, an ALS patient from Japan, lost his ability to speak due to a tracheotomy. However, his life took a positive turn when he discovered NeuroNode.
- Control Bionics Partners with Help ALS SpeakControl Bionics and Help ALS Speak, a 501 (c)3 Organization dedicated to helping people with Amyotrophic Lateral Sclerosis (ALS), recently partnered to bring awareness and augmentative and alternative communication (AAC) solutions to people living with ALS.
- ASX Announcement: Appointment of CEOControl Bionics Ltd (ASX: CBL) is pleased to announce the appointment of Jeremy Steele as Chief Executive Officer and a member of the board, effective from 19 January 2023.
- Control Bionics Featured on the Special Education Inner Circle PodcastCatherine Whitcher, founder of the Master IEP Coach® Mentorship + Network and host of the Special Education Inner Circle Podcast, spoke about Control Bionics’ NeuroNode Trilogy in her latest episode. Listen now!
Leadership
Board of Directors
CEO and Managing Director
Jeremy Steele
Jeremy has over 25 years of global corporate experience in a wide range of industries including healthcare, technology, financial services and retail. Jeremy has been both an investor and operator and most recently was Global CEO of CardioScan, and outsourced cardiac diagnostics business operating in 10 countries.
Jeremy has a Bachelor of Commerce from the University of Adelaide and was appointed to CEO and Managing Director of Control Bionics in early 2023.
Chairman and Non-Executive Director
Stephen Rix
Stephen is an experienced chairman, director and chief executive with a strong background in financial services, private equity and funds management. Stephen is passionate about helping companies grow and has 20 years’ experience as Chair doing this with Travelex Asia Pacific- the international foreign exchange group, Bennelong Funds Management Group and Australia’s newest digital bank, Avenue Bank.
Stephen is a director of Allen & Unwin Pty Ltd, Australia’s leading independent book publisher and has previously been a director of two listed companies including Colonial First State Private Capital Ltd. Stephen also served for 20 years as a trustee of the Australian Cancer Research Foundation which has funded more than $200m of leading cancer research innovation in Australia.
Stephen has been an investor in Control Bionics since 2016.
Board Member
Rob Heard
Rob is a highly experienced Australian neurologist and brings to the Board many years of clinical and academic expertise. He has strong interests in neuroimmunology, neurodegenerative disorders and the biology of ageing. He has co-led an extremely successful research team which has made important breakthroughs in the genetics of multiple sclerosis and he has published extensively in major medical journals. He is Conjoint Professor of Neurology, University of Newcastle. He contributed to the development by Xefco of the world’s first textile coatings active against SARS-CoV-2. He has a strong interest in pharma and biotechnology and is an active investor in this field.
Board Member
Damian Lismore
Damian has held a number of Directorships and has extensive commercial, international and listed company experience (both ASX and NASDAQ), covering many industries including healthcare and technology. In his executive career, he held CEO, CFO and Company Secretarial roles and continues to act as an advisor to CEOs, boards and business owners. Damian joined the Control Bionics board in September 2020 and is a Graduate Member of Australian Institute of Company Directors, Member of Chartered Accountants Australia and New Zealand, Fellow of Chartered Accountants in Ireland and holds a BA (Honours) Accountancy.
Non-Executive Director
Stephanie Phillips
Stephanie brings experience in medicine, academia and business to the board of Control Bionics. She is a senior specialist anaesthetist and clinical associate professor at the Australian National University. She has served on many Boards, both academic and commercial. She was the inaugural Chair of the Scientific Prizes, Awards and Research Committee (SPARC) of the Australian Society of Anaesthetists. Her recent research interest is intraoperative monitoring of neuromuscular blockade.
Stephanie holds a Bachelor of Medicine from the University of Newcastle, is a Fellow of both the Royal College and Australian & New Zealand College of Anaesthetists and a Graduate of the Australian Institute of Company Directors. She joined the board of Control Bionics Ltd in March 2025.
Company Secretary
Brett Crowley
Brett is a practicing solicitor and a former Partner of Ernst & Young in Hong Kong and Australia, and of KPMG in Hong Kong. He is a former Senior Legal Member of the NSW Guardianship Tribunal and the NSW Civil and Administrative Tribunal.
Brett has extensive ASX-listed company experience. He is currently chairman of Jatcorp Limited (ASX:JAT) and company secretary of three other ASX-listed companies.